Subscribe Past Issues Translate ▼



INVEST LIKE A PRO, WITH THE PROS!





See the new <u>Capital Ideas Digest</u> for a technology idea which is a leader in its sector, has strong financial backing, and some are saying reminds them of **Shopify** in the early days.

And watch our <u>new interview</u> with one of the leaders of **Contobox** (private), a company pushing digital advertising into the future.

www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

April 10, 2019

Written & compiled by Mark Bunting, Publisher, Capital Ideas Media



CANADIAN ANALYSTS' CALLS

Bonterra Energy (TSX:BNE) gets upgraded to "outperform" by RBC Dominion Securities and the price target is raised to \$11.75 (Canadian) from \$9.75.

Cenovus Energy (TSX:CVE). Credit Suisse moves the price target to \$17 from \$15.



U.S. ANALYSTS' CALLS

INITIATIONS

Tencent (OTC:TCEHY) gets started at "outperform" at Oppenheimer with a \$55 (U.S.) target.

**

Nordstrom (NYSE:JWN) gets upgraded to "overweight" by Keybanc on the strength of its online offering.

Under Armour (NYSE:UAA).

A Citi analyst has assumed coverage from a colleague upgrading the stock to a "buy" and moving the target to \$29 from \$23.

Nike (NYSE:NKE). The same analyst lifts the target to \$100 from \$96 and maintains a "buy", calling the shoe and apparel company "one of a kind".

Disney (NYSE:DIS) gets upgraded to "outperform" by BMO Nesbitt Burns with the target hiked to \$140 from \$114. Disney holds its Investor Day tomorrow.

STOCKS THAT MAY MOVE

Helius Medical (TSX:HSM;NASDAQ:HSDT).

Our contributor Fabrice Taylor always warned with this stock that there was the possibility of a binary event and that it was high risk/reward.

He said the FDA could approve its device for treatment of chronic balance deficit due to

mild-to-moderate traumatic brain injury when used with physical therapy, or it could decline it.

The latter has happened and the stock is **down** 56% in U.S. pre-market trading.

The Helius device is approved in Canada and the company says it's going to continue to gather data in the U.S. to try to get the device approved.

I emailed the CEO of Helius the other day requesting an interview and have yet to hear back.

Granite REIT (TSX:GRT.UN) is buying the leasehold interest in two properties in Mississauga, Ontario for \$154 million (Canadian).

Cannabis One Holdings (CSE:CBIS) is buying some assets from Honu Enterprises out of Washington for up to \$10.3 million in shares.

High Tide (CSE:HITI) has arranged a non-brokered private placement to sell up to 10,000 convertible debentures at \$1,000 each for up to \$10 million. The offering is anchored by an order from Aphria (TSX:APHA;NYSE:APHA) for \$4.5-million.

Levi Strauss (NYSE:LEVI) swung to a profit of \$146 million from a tax-related loss last year in its first quarterly report since returning to the

public markets last month as revenue rose 7%.

Netflix (NASDAQ:NFLX) is in talks to buy the historic Egyptian Theatre in the heart of Hollywood in order to host film premieres and industry events.

Alphabet (NASDAQ:GOOGL) will stream live broadcasts of all 230+ regular season and playoff games of sports league NBA 2K League.

MARKETS

The TSX and U.S. stock indices have started slightly higher.

CURRENCIES


The Canadian dollar is lower by 0.2% at \$0.7488 (U.S.).

COMMODITIES

West Texas Intermediate is up 0.6% near a five month high at \$64.39 a barrel.

Gold is down a bit at \$1,306.70 an ounce.

Daily Update



Paul Pedersen, NextLeaf Solutions (CSE:OILS) Co-Founder, CEO

Sponsor content

Bay Street investors are excited by the U.S. patent *Nextleaf Solutions (CSE:OILS)* has won for the extraction and purification of cannabinoids.

We talk to Paul Pedersen, the co-founder and CEO of NextLeaf, who also helped to start Peace Naturals before selling it to Cronos Group.

The newly public Nextleaf, out of Coquitlam, B.C., has **beaten multi-billion dollar companies to the punch** putting it ahead of the pack leading up to "**Legalization 2.0**" in Canada, this fall.

Nextleaf is gearing up to provide cannabis companies with pure, tasteless, odourless and

standardized cannabis oils for use in edibles and many other products.

Revolutionize the staid, old world of insurance. That's what *Karn Saroyan* is trying to do.

He's the co-founder and CEO of *Cover*, a nationally licensed insurance brokerage backed by some big dollar venture capital such as Tencent.

Watch the latest interview in our entrepreneur and startup series.

Please email questions, comments or concerns to:


customercare@capitalideasresearch.com

Access, ideas and insight.

Mark Bunting Publisher, Capital Ideas Media

www.capitalideasmedia.com





The information and recommendations made available here ("Information") by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

Add us to your address book

update subscription preferences

This email was sent to << Email Address>>

why did I get this? unsubscribe from this list update subscription preferences

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada